Oncotarget, a leading scientific journal, was the sponsor of the Gordon Research Conference. The convention aimed at highlighting latest research on functions of matrix metalloproteinases (MMPS) and how endogenous mechanisms control behavior of MMPS. Discussions centered on opportunities for new research and how the studies could guide scientists in the designing of metalloproteinase-targeted modulators to treat human diseases.
Know more: https://www.researchgate.net/journal/1949-2553_Oncotarget
When the Research Began
Since scientists discovered matrix metalloproteinases (MMPs), ADAM and ADAMTS as tissue remodeling enzymes more than 50 years ago, they have identified them as factors that contribute to diseases such as cancer, neurodegeneration, and inflammatory diseases. After the discovery, scientists marked them as a drug target since they are both good and bad actors.
Early clinical trials
Early clinical trials of use of metalloproteinases as inhibitors were unsuccessful for several reasons. First, not all scientists appreciated functions of individual metalloproteinases. Notably, while some metalloproteinases contribute to diseases, recent research has shown that several others prevent diseases, facilitate regeneration, reduce inflammation, and support several beneficial functions. Thus, scientists aim to discover particular functions of individual MMPs and understand how the activities are controlled. This will allow them to identify specific harmful function that can be treated with new therapies.
Oncology is a scientific journal whose mission is to rapidly and widely spread scientific results. The publication also aims at maximizing impact of scientific studies via meaningful review and eliminating barriers between specialties. The journal accepts publications on several related fields such as endocrinology, neuroscience, ageing, and cell biology. This has resulted into meaningful collaborations between scientists who specialize in different areas.
Oncotarget, which was founded in 2010, is released every week. It is a highly ranked medical journal that is indexed in PubMed, Index Medicus, and Scopus. The publication is released online and can be easily accessed by everyone globally. The editors-in-chief of Oncotarget are Andrei Gudkov and Mikhail Blagosklonny. Blagosklonny is a professor in Oncology at Roswell Park Institute and has published in more than 200 papers in scientific journals. Gudkov is also a professor and a medical research vice president at Roswell Park Institute. Visit Oncotarget’s profile page at facebook.com
Troy McQuagge is the President and the Chief executive officer of USHEALTH Group. Recently the head of USHEALTH was named as the Gold Winner in the position of the Chief Executive Officer of the year. The One Planet Awards is one of the most respected awards in the world which since its inception has been honoring enterprises as well as professional individuals all over the world across all sectors. Interested individuals, as well as organizations, have the opportunity to submit their names for nomination purposes. One Planet Awards honor individuals, non-profit companies, private as well as public organizations regardless of their sizes and more information click here.
Mr. Troy was honored to be named by One Planet as the Chief Executive Officer of the year in the Gold category. Troy said that the Award did not belong to himself. Instead, he dedicated the award to USHEALTH Group staff for their endless efforts in providing quality health services. Mr. Troy further stated that the award was an evidence of the firm’s dedication to the delivery of affordable healthcare services to their clients. USHEALTH Group has been offering the best healthcare products and services and meeting the needs of their clients.
Troy McQuagge is a leader at USHEALTH Group, and he had the responsibility of serving as the President and the Chief Executive Officer of the Medical care facility. Mr. McQuagge joined USHEALTH in 2010 and through his hard work and the experience he had he took the responsibility of serving the company by reorganizing the group’s delivery agencies. His hard work and commitment saw Troy climb the career ladder and he was appointed as the Chief Executive Officer of the company in 2014. During his team as the Chief Executive Officer, the medical facility has experienced tremendous growth and Troy’s lacrosse camp.
Troy McQuagge began his career serving at Allstate Insurance Company; he later joined United Insurance Companies at the Student Insurance Division. Troy is a go-getter and very determined a character that led him to be named as the President of United Insurance Companies Ins in 1997. Before being the President and the Chief Executive Officer of USHEALTH Group, Troy acted as the Vice President and the Chief Marketing Officer of USHEALTH Group. He is a graduate with a B.A Degree from the University of Central Florida and Troy on Facebook.
The Lung Institute is a national leader in stem-cell treatments for diseases of the lung, such as COPD, pulmonary fibrosis, and emphysema. With locations in five cities, the institute specializes in helping to improve the quality of life for people afflicted with these types of health issues. According to the Baylor College of Medicine and Lung Institute’s internal research, more than 84% of those who sought therapy for COPD with the institute experienced improved quality of life.
Chronic lung diseases are notoriously difficult to treat. The Lung Institute has pioneered a number of techniques employing stem cells and plasma transplantation to regenerate tissue that has been gradually damaged over the years. Stem cell treatments rely on a property called plasticity, meaning the ability of cells from one part of the body to carry on the same function in another part of the body. The type of stem-cell treatments that the Lung Institute uses only use the patient’s own stem cells, not those of others.
Lung Institute physicians are active at international medical conferences and are highly regarded as experts in this nascent field. Dr. Jack Coleman recently gave a presentation at a conference in Padua, Italy, in which he outlined recent developments in regenerative treatments and his view of the potential these techniques have for the future. Dr. Coleman’s lecture was critical of the status quo in developing new treatment modalities. In Coleman’s view, the current system is too slow and non-responsive, and he hopes the United States and other countries will adopt new practices drawing on the examples of other countries which have streamlined these processes.
To read more, go to supplementpolice.com.
Lung Institute’s Twitter: https://twitter.com/lunginstitute?lang=en